RUBY Trial of Gene Editing Cell Therapy EDIT-301 Now Enrolling

RUBY Trial of Gene Editing Cell Therapy EDIT-301 Now Enrolling

311750

RUBY Trial of Gene Editing Cell Therapy EDIT-301 Now Enrolling

Enrollment is underway for a Phase 1/2 trial evaluating the safety and efficacy of EDIT-301, an experimental gene editing cell therapy for people with sickle cell disease (SCD). The trial, called RUBY (NCT04853576), had been cleared for launch by the U.S. Food and Drug Administration earlier this year, and will be conducted at five sites across the U.S. Editas Medicine, the therapy’s developer, is expecting dosing to start in the first half of 2022, according…

You must be logged in to read/download the full post.